TY - GEN
T1 - Fluorescently labeled bevacizumab in human breast cancer
T2 - European Conference on Biomedical Optics, ECBO 2017
AU - Koch, Maximilian
AU - de Jong, Johannes S
AU - Glatz, Jürgen
AU - Symvoulidis, Panagiotis
AU - Lamberts, Laetitia E
AU - Adams, Arthur L.L.
AU - Kranendonk, Mariëtte E G
AU - Terwisscha van Scheltinga, Anton G T
AU - Aichler, Michaela
AU - Jansen, Liesbeth
AU - de Vries, Jakob
AU - Lub-de Hooge, Marjolijn N
AU - Schröder, Carolien P.
AU - Jorritsma-Smit, Annelies
AU - Linssen, Matthijs D
AU - de Boer, Esther
AU - van der Vegt, Bert
AU - Nagengast, Wouter B
AU - Elias, Sjoerd G.
AU - Oliveira, Sabrina
AU - Witkamp, Arjen J.
AU - Mali, Willem P.Th M.
AU - Van der Wall, Elsken
AU - Garcia-Allende, Beatriz P
AU - van Diest, Paul J.
AU - de Vries, Elisabeth G E
AU - Walch, Axel
AU - van Dam, Gooitzen M
AU - Ntziachristos, Vasilis
N1 - Publisher Copyright:
© 2017 SPIE-OSA.
PY - 2017
Y1 - 2017
N2 - In-vivo fluorescently labelled drug (bevacizumab) breast cancer specimen where obtained from patients. We propose a new structured method to determine the optimal classification threshold in targeted fluorescence intra-operative imaging.
AB - In-vivo fluorescently labelled drug (bevacizumab) breast cancer specimen where obtained from patients. We propose a new structured method to determine the optimal classification threshold in targeted fluorescence intra-operative imaging.
KW - Clinical applications
KW - Imaging systems
KW - Medical and biological imaging
UR - http://www.scopus.com/inward/record.url?scp=85032258866&partnerID=8YFLogxK
U2 - 10.1117/12.2286062
DO - 10.1117/12.2286062
M3 - Conference contribution
AN - SCOPUS:85032258866
SN - 9781510612808
VL - Part F61-ECBO 2017
BT - European Conference on Biomedical Optics, ECBO 2017
PB - OSA - The Optical Society
Y2 - 25 June 2017 through 29 June 2017
ER -